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Equine mesenchymal stromal cells (MSC) are commonly transported, chilled or frozen, 
to veterinary clinics. These MSC must remain viable and minimally affected by culture, 
transport, or injection processes. The safety of two carrier solutions developed for opti-
mal viability and excipient use were evaluated in ponies, with and without allogeneic cord 
blood-derived (CB) MSC. We hypothesized that neither the carrier solutions nor CB-MSC 
would elicit measurable changes in clinical, hematological, or biochemical parameters. 
In nine ponies (study 1), a bolus of HypoThermosol® FRS (HTS-FRS), CryoStor® CS10 
(CS10), or saline was injected IV (n = 3/treatment). Study 2, following a 1-week washout 
period, 5 × 107 pooled allogeneic CB-MSCs were administered IV in HTS-FRS following 
24  h simulated chilled transport. Study 3, following another 1-week washout period 
5 × 107 pooled allogeneic CB-MSCs were administered IV in CS10 immediately after 
thawing. Nine ponies received CB-MSCs in study 2 and 3, and three ponies received 
the cell carrier media without cells. CB-MSCs were pooled in equal numbers from five 
unrelated donors. In all studies, ponies were monitored with physical examination, and 
blood collection for 7 days following injection. CD4 and CD8 lymphocyte populations 
were also evaluated in each blood sample. In all three studies, physical exam, complete 
blood cell count, serum biochemistry, and coagulation panel did not deviate from estab-
lished normal ranges. Proportions of CD4+ and CD8+ lymphocytes increased at 168 h 
postinjection in CB-MSC treatment groups regardless of the carrier solution. Decreases 
in CD4+/CD8+ double positive populations were observed at 24 and 72 h in CB-MSC-
treated animals. There was no difference in viability between CB-MSCs suspended in 
HTS-FRS and CS10. HTS-FRS and CS10 used for low volume excipient injection of 
MSC suspensions were not associated with short-term adverse reactions. HTS-FRS 
and CS10 both adequately maintain CB-MSC viability following hypothermic or frozen 
simulated transport, respectively. CB-MSCs do not elicit clinical abnormalities, but allo-
geneic stimulation of CD4+ and CD8+ lymphocyte populations may occur. Future studies 
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should include in  vitro or in  vivo evaluation of cell-mediated or adaptive immunity to 
autologous, identical allogeneic, or MSC originating from additional unrelated individuals 
in order to better characterize this response.
Keywords: horse, equine, stem cell transport, hypothermic, cryopreservation
inTrODUcTiOn
Equine mesenchymal stromal cells (MSCs) have been isolated 
from a variety of tissues including bone marrow (1–3), adipose 
tissue (3, 4), umbilical cord blood (CB) (5, 6), and umbilical 
cord tissue (3, 7). Collection of CB is a non-invasive source of 
CB-MSCs, which are highly proliferative, capable of trilineage 
differentiation, and possess lymphocyte suppressive properties 
in mixed lymphocyte reactions (5, 6, 8–10).
Currently in veterinary medicine, MSC preparations are avail-
able following a period of ex vivo culture expansion for autologous 
administration. Such use is limited by the several weeks needed 
for preparation of cultured MSC from autologous cell or tissue 
samples, effectively excluding immediate treatment of acute 
injuries. Allogeneic MSC use allows treatment of acute lesions 
with prescreened and characterized MSC cultures. In fact, the 
future of regenerative medicine may include cryopreserved MSC 
suspensions that have been screened for desirable characteristics 
being stocked at veterinary primary care facilities for immediate 
treatment at the time of diagnosis of injury.
Allogeneic MSC use has been shown to be safe for in  vivo 
intravenous (11, 12), intraarticular (13–16), intradermal (17), 
intrathecal (18), and intralesional-tendon injection in the horse 
(19–21). Although there are reports of an increased inflamma-
tory response following intraarticular injection of allogeneic 
MSC (14), inflammation subsided quickly and no difference in 
immune response was detected between allogeneic and autolo-
gous MSC (22).
Regardless of MSC source or allogeneic/autologous use, 
MSC suspensions require transport from laboratory to a veteri-
nary clinic, usually by commercial overnight carrier. Decreased 
MSC viability has been demonstrated following transportation 
in various media (23, 24). One strategy reported to slow the 
decrease in MSC viability is to transport MSC in serum-
containing media. If the serum is allogeneic or xenogeneic in 
nature, then it is often recommended that the MSCs undergo 
multiple washes prior to injection to remove the majority 
of foreign antigens introduced by the serum. This process is 
inconvenient, associated with a decrease of total MSC numbers 
and increases the risk of bacterial contamination. A cell carrier 
media that requires removal as described, prior to injection of 
the MSC, is referred to as an ancillary media. Excipient media 
is a cell-carrier solution that provides necessary support but 
is otherwise unreactive and can be injected with the MSC. 
Excipient media allows a convenient and more standardized 
final product formulation since no manipulations are required 
at the time of treatment. HypoThermosol® FRS (HTS-FRS, 
BioLife Solutions, Bothell, WA, USA) and CryoStor® (CS, 
BioLife Solutions, Bothell, WA, USA) are cell preservation 
media for excipient use with chilled or frozen mammalian 
cells, respectively. These media are serum free and protein free, 
commercially available, procured with adherence to current 
Good Manufacturing Practices (GMP) and are optimized for 
maintaining cell viability at 2–8°C or in a frozen state. HTS-
FRS has been shown to preserve viability of cells, tissues, or 
organs better than cells, tissues, or organs transported in many 
other media (25–30). These media mimic intracellular solute 
concentrations, which minimize solute gradients across cell 
membranes providing an optimal environment for hypother-
mic or cryogenic (DMSO added) storage (29, 31). CryoStor 
CS10 is a cryomedia pre-formulated with 10% DMSO. In our 
lab, improved viability over non-serum-containing media and 
equivalence to serum-containing media has been demonstrated 
in preservation of equine MSC chilled in HTS-FRS or frozen in 
CS10 (see File S1 in Supplementary Material). Additionally, our 
research group has compared HTS-FRS to phosphate buffered 
saline (PBS) for administration by intra-articular injection. A 
similarly mild, clinically insignificant inflammatory reaction 
was observed following intra-articular injection of both PBS 
and HTS-FRS (see File S2 in Supplementary Material).
We hypothesized that the carrier solutions alone or in com-
bination with CB-MSC would not elicit measurable changes in 
clinical parameters, hematological including CD4+ and CD8+ 
counts and serum biochemical parameters, in healthy ponies.
MaTerials anD MeThODs
collection, isolation, and  
culture of cB-Msc
Cryopreserved CB-MSC cultures from frozen stock were 
used. CB-MSCs were procured as previously described (5, 6) 
Previously, CB-MSCs isolated under identical conditions dis-
played a consistent phenotype before and after cryopreservation. 
This included high expression of CD29, CD44, CD90, and absent 
or low expression of major histocompatibility complex (MHC) 
class I, MHC-II, CD4, CD8, CD11a/18, and CD73 (10). CB-MSC 
cultures from five unrelated donor foals were expanded in culture 
to achieve necessary MSC numbers in DMEM-containing 30% 
FBS, 1% Penicillin/Streptomycin, and 1% l-glutamine. CB-MSC 
cultures suspended in HTS-FRS had been cryopreserved once, 
were between passage 6 and passage 7, and had been cultured for 
a total of 42–50 days. CB-MSC cultures suspended in CS10 had 
been cryopreserved once, were between passage 4 and passage 
5, and had been cultured for a total of 35–40 days. Twenty-four 
hours prior to injection, MSC suspended in HTS-FRS were 
detached from cell culture flasks using trypsin EDTA, washed 
once in PBS, then suspended in HT-FRS and stored in a reusable 
temperature-controlled shipping container (Greenbox 2–8°C 
thermal management system, ThermoSafe®, Arlington Heights, 
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IL, USA) in the lab until just prior to the time of injection. 
MSCs suspended in CS10 were detached from cell culture flasks 
18  days prior to injection, gradually frozen at a rate of −1°C/
min to −80°C before transfer to liquid nitrogen storage. These 
CB-MSCs were transported to the research farm on dry ice and 
thawed under lukewarm tap water approximately 20 min prior to 
injection. Acellular vials of HTS-FRS or CS10 (to act as controls) 
were handled in an identical manner to their respective CB-MSC 
containing vials.
research animals
Twelve mature healthy ponies (4 females, 8 males; age 4 years) 
that had not received any medications for at least 2 months were 
used in these studies. Physical exam and baseline CBC, bio-
chemistry, and coagulation profiles indicated all horses were free 
from obvious disease. All procedures complied with institutional 
animal care committee protocols approved for this study (Koch, 
University of Guelph Animal Care Protocol #3247).
experimental Protocol
Study 1
Ponies were randomly assigned into treatment groups by lottery. 
Prior to injection, baseline (0 h) physical examination was per-
formed including temperature, pulse, respiration, and demeanor, 
and 12 mL blood was collected from the jugular vein. A single 
10 mL injection of one of CS10 (n =  3), HTS-FRS (n =  3), or 
physiologic saline (n = 3) was administered to nine ponies into 
the jugular vein. The remaining three ponies were not used in 
study 1. Temperature, pulse, and respiration were recorded from 
all treated ponies at 0, 1, 3, 6, 12, 24, 48, 72, 168 h postinjection. 
About 12 mL of whole blood was collected from treated ponies at 
0, 1, 24, 72, and 168 h postinjection.
Study 2
Ponies were randomly assigned into treatment groups as indicated 
above. All 12 ponies received a single IV injection of either 10 mL 
HTS-FRS (n = 3) or 5 × 107 pooled allogeneic CB-MSC (1 × 107 
CB-MSCs from five unrelated MSC donors) (n = 9). Ponies were 
monitored, and blood samples collected as indicated above.
Study 3
Ponies were once again randomly assigned into treatment groups 
as indicated above. All 12 ponies received a single IV injection of 
either 10 mL CS10 (n = 3) or 5 × 107 pooled allogeneic CB-MSCs 
(1 × 107 CB-MSC from five unrelated MSC donors) suspended in 
CS10 (n = 9). Ponies were monitored and blood samples collected 
as indicated above.
evaluation of Post-Transport Viability
Following injection, vials that had been used to transport 
CB-MSC suspensions were transported back to the laboratory at 
room temperature where MSC viability was calculated using the 
residual ~100–200 μL of CB-MSC suspension in each vial using a 
hemocytometer counting chamber and the trypan blue exclusion 
assay. In total, CB-MSC suspensions had been stored under 
transport conditions (2–8°C in study 2 and dry ice cooler in study 
3) for 24 h followed by approximately 2 h at room temperature 
before viability measurements were obtained.
evaluation of Blood samples
Blood samples were submitted to our veterinary diagnostic 
laboratory for complete blood count (Avida 2120i, Siemens 
Canada, Oakville, ON, USA), serum biochemistry profile, and 
coagulation profile (PT, PTT, fibrinogen). In addition, CD4+ and 
CD8+ lymphocyte populations were analyzed by flow cytometry. 
Briefly, whole blood was prepared by combining 100 μL of whole 
blood with 1400 μL 1× RBC lysis buffer (9 parts dH2O, 1 part 10× 
RBC lysis buffer (1.7M NH4Cl, 0.1M KHCO3, 1 mM NH4EDTA, 
pH 7.3)) and incubated 5 min at room temperature. About 1 mL 
flow buffer (PBS/1% horse serum, 15  mM Na azide, 0.5  mM 
NA4EDTA) was added and spun at 1200 rpm for 5 min. Separate 
15 min incubations followed with CD4 and then CD8 antibod-
ies (catalog # MCA108PE & MCA1078F, AbD Serotec, Raleigh, 
NC, USA) with the cell pellet washed in flow buffer after each 
incubation. Finally, the cell pellet was suspended in flow buffer 
for flow cytometry (BD Accuri C6, BD Biosciences, Mississauga, 
ON, USA). Flow cytometry gates were set to first select a distinct 
cell population with size and granularity consistent with equine 
lymphocytes. From this population 10,000 cells were evaluated 
for CD4± and CD8± surface markers. Gates to differentiate 
cell populations were maintained consistent throughout the 
experiment.
statistical analysis
Raw data from physical exams, CBC, biochemistry profiles, and 
coagulation profiles were imported into statistical software (SAS 
9.2, SAS institute, Carey, NC, USA). Data were randomly blocked 
by horse and were in the form of a split plot in time design; hence, 
there were repeated measures in time. Data were analyzed using 
a general linear mixed model to evaluate fixed effects (treatment, 
time and treatment by time interaction) and random effects (horse) 
using the PROC MIXED function. Various error structures, 
supplied by the statistical analysis software (AR, ARH, TOEP, 
banded TOEP 2-TOEP (t-1), TOEPH, banded TOEPH2-TOEPH 
t-1, unstructured, banded unstructured 2-banded unstructured 
t-1) were tested, and one error structure was selected for each 
model based on the lowest Akaike information criterion (AIC). 
To improve the power of each study identical treatments were 
combined between studies 1–2 (HTS-FRS) and studies 1–3 
(CS10) after determining there was no study effect in the linear 
model. Residual analysis was performed on each dataset to deter-
mine if ANOVA assumptions were met, detect potential outliers, 
and evaluate the need for data transformation. The residuals 
were formally tested for normality using the four tests offered by 
SAS (Shapiro-Wilk, Kolmogorov–Smirnov, Cramer-von Mises, 
Anderson-Darling) and plotted against the predicted values 
and explanatory variables used in the model. For the purpose of 
determining statistical significance, α was set at 0.05.
Data resulting from postinjection CB-MSC viability measure-
ments were analyzed in a similar manner using the panel of tests 
FigUre 1 | (a) Temperature, pulse, and respiration rates of ponies receiving a 10 mL IV bolus of HypoThermosol® FRS (HTS-FRS) (n = 6), CryoStor® CS10 (CS10) 
(n = 6), or saline (n = 3). (B) Temperature, pulse, and respiration rates of ponies receiving an IV injection of 5 × 107 pooled allogeneic umbilical cord blood derived 
mesenchymal stromal cells (CB-MSC) suspended in 10 mL HTS-FRS (n = 9) or 10 mL HTS-FRS alone (n = 6). (c) Temperature, pulse, and respiration rates of 
ponies receiving an IV injection of 5 × 107 pooled allogeneic umbilical cord blood derived mesenchymal stromal cells (CB-MSC) suspended in 10 mL CS10 (n = 9) or 
10 mL CS10 alone (n = 6). Data points indicate mean response with error bars indicating 95% CI. *p < 0.05, **p < 0.01, ***p < 0.001 compared to the 
corresponding time point. In study 1, subscript letters specifies the treatments that the difference occurs between, C-CS10, H-HTS-FRS, S-Saline.
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for normality and methodology for selecting an appropriate error 
structure as indicated above. Following this analysis, a general 
linear model and the PROC MIXED function (SAS 9.2, SAS 
Institute, Cary, NC, USA) were performed to evaluate solution 
effects on MSC viability.
resUlTs
Following statistical analysis, data were standardized by dividing 
by the pretreatment mean. This allowed the many values resulting 
from the CBC, biochemistry profile, and coagulation panel to be 
plotted on the same scale.
Physical exam parameters (temperature, pulse rate, and 
respiration rate) remained within normal limits throughout the 
duration of all three studies (Figure 1). Differences in tempera-
ture and respiratory rate were observed as indicated in Figure 1. 
Throughout the duration of the study, all animals remained 
bright, alert, and responsive.
CBC, biochemistry profile, and coagulation profiles did not 
deviate from the normal ranges provided by the diagnostic labo-
ratory. Significant differences in parameters are indicated in File 
S3 in Supplementary Material (for study 1) and Figures 2–7 for 
studies 2 and 3.
Flow cytometry of whole blood samples to assess CD4+ 
and CD8+ lymphocyte populations revealed a significant 
decrease in the double positive (CD4+, CD8+) population 24 
and 72 h following MSC injection compared to matched HTS-
FRS (p = 0.03, <0.0001, respectively) and CS10 (p < 0.0001, 
0.04, respectively) controls. Significant elevation of CD4+ 
and CD8+ lymphocyte populations were observed at 168 h in 
animals receiving pooled allogeneic CB-MSC suspended in 
HTS-FRS [(CD4+: p = 0.03, CD8+: p = 0.03) and (CS10 CD4+: 
p = 0.02, CD8+: 0.03)]. The CD4:8 ratio was decreased at 72 h 
in CB-MSC in HTS-FRS-treated animals compared to HTS-
FRS-treated animals alone (p = 0.04). The CD4:8 ratio was also 
decreased at 24 and 72 h in CS10 treated animals compared 
to CS10 treated animals alone (p =  0.04, 0.001, respectively, 
Figures 8 and 9).
Post injection the viability of residual CB-MSC suspensions 
was not different between CB-MSC suspended in HTS-FRS 
(mean-74.3, 95% CI: 69.5–78.5%) or CS10 (mean-76.0, 95% 
CI: 71.4–80.0%), p =  0.6, File S3-figure SE in Supplementary 
Material.
FigUre 2 | Percent difference from pre-injection measurements (black dotted line) of complete blood count (a) 0 h, (B) 1 h, (c) 24 h (D) 72 h, (e) 
168 h following intravenous injection of 5 × 107 pooled allogeneic cB-Msc derived from five horses. 10 mL HypoThermosol® (HTS-FRS) control. Error 
bars represent 95% confidence interval. Different letters indicate statistical differences between treatment and control groups for a specific parameter.
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DiscUssiOn
We report no adverse clinical reaction to the IV injection of 
10 mL of either HTS-FRS or CS10 in healthy 4-year-old ponies. 
Although a number of statistical differences were detected in 
physical exam, CBC, biochemistry profile, or coagulation profile 
parameters, at no time were mean parameters outside of previously 
established normal ranges in a clinically significant manner. We 
consider these differences as minor variations from normal due 
to random variation within the herd and detection of differences 
as a result of chance. A similar lack of inflammatory response has 
been observed following IA injection of HTS-FRS in horses (see 
File S2 in Supplementary Material). Likewise, no adverse reac-
tions were observed following IV injection of CB-MSC pooled 
from five unrelated horses. No abnormalities were detected in 
CBC, biochemistry, or coagulation profiles where mean values 
did not differ from established normal ranges. This indicates that 
although statistically different, physical examinations and routine 
blood work did not detect clinically significant abnormalities 
between treatment groups.
We did, however, observe differences in CD4+, CD8+, and 
double positive (both CD4+ and CD8+ receptors) lymphocyte 
populations. In general, we observed an increase in CD4+ 
and CD8+ populations at 168  h postinjection and a decrease 
in the double positive population at the 24 and 72  h time 
points as well (Figure 9). Increases in the CD4+ and CD8+ 
populations suggest allogeneic stimulation of both T-helper 
and Cytotoxic T-cell populations, respectively. While CD4+ 
FigUre 3 | Percent difference from pre-injection measurements (black dotted line) of coagulation profile (a) 0 h, (B) 1 h, (c) 24 h (D) 72 h, (e) 168 h 
following intravenous injection of 5 × 107 pooled allogeneic cB-Msc derived from five horses. 10 mL HypoThermosol® (HTS-FRS) control. Error bars 
represent 95% confidence interval. Different letters indicate statistical differences between treatment and control groups for a specific parameter.
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and CD8+ lymphocytes are often considered mutually exclusive 
phenotypes and reportedly rare in human and dog (32, 33), 
they represent a high proportion of lymphocytes in swine and 
chickens (34–36). While our proportion of double positive 
lymphocytes was relatively small (less than 10%); lymphocytes 
originating from Thoroughbred horses and Connemara ponies 
have been reported to contain as high as 39% double positive 
lymphocytes (37). Although little is known about the function 
of this population, they are thought to appear or disappear from 
CD4+ lymphocytes through the gain or loss of the CD8+ recep-
tor (37, 38). Interestingly, in the presence of MSC, CD4+/CD8+ 
double positive lymphocytes appear resistant to MSC-mediated 
lymphocyte suppression yet quickly disappear following a 
period of in vitro culture (37).
The viability reported following here following hypothermic 
storage or cryopreservation is considerably less than what we 
report under controlled conditions (File S1 in Supplementary 
Material) or that is reported by others using human BM-MSC 
FigUre 4 | Percent difference from pre-injection measurements (black dotted line) of biochemistry profile (a) 0 h, (B) 1 h, (c) 24 h (D) 72 h, (e) 168 h 
following intravenous injection of 5 × 107 pooled allogeneic cB-Msc derived from five horses. 10 mL HypoThermosol® (HTS-FRS) control. Error bars 
represent 95% confidence interval. Different letters indicate statistical differences between treatment and control groups for a specific parameter.
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(29). We attribute this difference to the time (~2 h) MSC samples 
spent at room temperature while injections were being performed 
and in transit back to the laboratory. Regardless of this, we report 
similar viability of MSC samples despite sample differences in the 
preservation method.
CB-MSCs isolated under similar conditions to those used 
in this study have consistently shown lymphocyte suppressive 
effects in vitro (10). These MSCs express CD29, CD44, CD90, 
and low/absent expression of MHC I, MHC II, CD4, CD8, 
CD11a/18, and CD73 markers (10). Despite a supposed lack 
of both MHC I and MHC II on these CB-MSCs, a significant 
shift of in vivo CD4+ and CD8+ lymphocyte populations may 
indicate a possible allogeneic reaction and a need to confirm the 
lack of MHCI/II markers of the CB-MSC populations injected. 
Additional research in these animals should include Fox3p 
staining to evaluate CD4+ regulatory T-lymphocytes (Treg) 
populations, administration of additional dose(s) of MSC with 
similar monitoring, or harvest of peripheral blood lymphocytes 
FigUre 5 | Percent difference from pre-injection measurements (black dotted line) of complete blood count (a) 0 h, (B) 1 h, (c) 24 h (D) 72 h, (e) 
168 h following intravenous injection of 5 × 107 pooled allogeneic cB-Msc derived from 5 horses. 10 mL CryoStor® CS10 (CS10) control. Error bars 
represent 95% confidence interval. Different letters indicate statistical differences between treatment and control groups for a specific parameter.
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for evaluation for MSC-mediated lymphocyte suppressive 
properties. The immune response resulting from subsequent 
CB-MSC doses may reveal significant information as to the 
mechanisms by which allogeneic CB-MSCs elicit possible 
immune reaction. Numerous reports indicate allogeneic MSCs 
administered by various routes may prime the immune system 
for a greater response, following future MSC injections or 
organ transplant in the recipient animal, as reviewed by Griffin 
and colleagues (39). Such investigation may indicate formation 
of alloantibodies, increased CD8+ lymphocyte response, or the 
duration any potential immunity persists. This understanding 
would advance the understanding of potential ways allogeneic 
MSCs may be used to avoid stimulation of unwanted immune 
reactions. Although similar to horses in many ways the pony 
may be a more sensitive in vivo model for study of potentially 
immunogenic substances. Ponies express increased polymor-
phonucleocyte function and greater inflammatory response to 
inflammatory stimuli (40, 41). As a result, when evaluating a 
FigUre 6 | Percent difference from pre-injection measurements (black dotted line) of coagulation profile (a) 0 h, (B) 1 h, (c) 24 h, (D) 72 h, and (e) 
168 h following intravenous injection of 5 × 107 pooled allogeneic cB-Msc derived from 5 horses. 10 mL CryoStor® CS10 (CS10) control. Error bars 
represent 95% confidence interval. Different letters indicate statistical differences between treatment and control groups for a specific parameter.
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potentially immunogenic substance for safety the pony model 
may reveal responses that would not be observed in adult 
horses.
Although the makeup of these current proprietary solutions is 
not publicly available, a similar intracellular-like first generation 
base formulation has been published when “hypothermosol” was 
first described (42, 43). Assuming CryoStor and HTS-FRS are 
similar in intracellular-like components (aside from DMSO in 
CryoStor) (29, 31) the main safety concern for administration 
of these solutions is the high levels of K+ (42.5 meq/L) in solu-
tion. While IV administration of hyperkalemic solutions is 
contraindicated, excipient injection of cell suspensions in small 
volumes especially to large animal species eliminates risk of 
inducing cardiac conduction abnormalities following injection, 
since administration of 10 mL/kg/h (approaching 0.5 meq/kg/h 
maximum safe administration rate of K+) is very unlikely to 
occur when small volumes are used for regenerative medicine 
purposes.
FigUre 7 | Percent difference from pre-injection measurements (black dotted line) of biochemistry profile (a) 0 h, (B) 1 h, (c) 24 h (D) 72 h, (e) 168 h 
following intravenous injection of 5 × 107 pooled allogeneic cB-Msc derived from 5 horses. CryoStor® CS10 (CS10) control. Error bars represent 95% 
confidence interval. Different letters indicate statistical differences between treatment and control groups for a specific parameter.
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In conclusion, HypoThermosol® FRS (HTS-FRS) and 
CryoStor® CS10 (CS10) used for low volume excipient injection 
of MSC suspensions was not associated with short-term adverse 
reactions. HTS-FRS and CS10 both adequately maintain CB-MSC 
viability following hypothermic or frozen simulated transport, 
respectively. CB-MSC does not elicit clinical abnormalities, but 
allogeneic stimulation of CD4+ and CD8+ lymphocyte popula-
tions may occur. Future studies should include in vitro or in vivo 
evaluation of cell-mediated or adaptive immunity to autologous, 
identical allogeneic, or MSC arising from additional unrelated 
individuals in order to more precisely determine the nature of 
this response.
FigUre 9 | cD4+, cD8+, cD4+/cD8+ (double positive), and cD4−/cD8− (double negative) lymphocyte populations following intravenous injection of 
5 × 107 pooled allogeneic cB-Msc derived from five horses. CryoStor® CS10 (CS10) control. *p < 0.05, **p < 0.01, ***p < 0.001.
FigUre 8 | cD4+, cD8+, cD4+/cD8+ (double positive), and cD4−/cD8− (double negative) lymphocyte populations following intravenous injection of 
5 × 107 pooled allogeneic cB-Msc derived from five horses. HypoThermosol® FRS (HTS-FRS) control. *p < 0.05, **p < 0.01, ***p < 0.001.
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